19
June 2018
iX Biopharma Ltd. is pleased to announce the approval by Therapeutic Goods Administration, the regulatory authority in Australia, for WAFESIL (sublingual sildenafil wafer)...
Read On10
May 2018
iX Biopharma Ltd. has reported results for the third financial quarter ended 31 March 2018 (unaudited).
Read OnSublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner.
Read OnThe Pharmacokinetics and Local Tolerability of a Novel Sublingual Formulation of Buprenorphine
Oxford Journal on Pain Medicine, 2017The absolute bioavailability of racemic ketamine from a novel sublingual formulation
British Journal of Clinical Pharmacology, 2013A Phase I Pharmacokinetic and Bioavailability Study of a Sublingual Fentanyl Wafer in Healthy Volunteers
Anesthesia and Analgesia, 20121 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com